Linkage Global’s ClickClack Chief Scientist Recognized for Coma Awakening Research as Company and Hospital Partner Launch Second-Stage Clinical Research

Rhea-AI Summary

Linkage Global (NASDAQ: UZX) announced that Professor Zeng Yan, Chief Scientist at ClickClack, an intellectual property partner of Linkage Global, received the “Clinical Contribution Award for Deep Coma Awakening” from the Coma Arousal and Rehabilitation Center for Brain Disorders at Guangdong Second Hospital of Traditional Chinese Medicine.

The award recognizes a two-year, uncontrolled, single-center observational study in 407 deep coma patients using a non-invasive protocol combining “micro-brain” sound wave music with traditional acupuncture. According to Linkage Global, 32 patients (7.86%) awakened and 252 (61.9%) showed ≥9-point increases on the Glasgow Coma Scale, but the company cautions these outcomes cannot be attributed to the protocol, are not evidence of safety or efficacy, and have not been peer reviewed or assessed by regulators.

Building on these data, Linkage Global and the Hospital are starting a second-stage (“Phase II”) investigational research program on non-pharmacological approaches to cognitive impairment and sleep disorders, which is not a regulated clinical trial phase and carries no assurance of completion, positive results, or commercial products.

Positive

• Two-year observational coma study completed with 407 patients and reported outcome metrics
• Reported 32 patient awakenings and GCS improvement ≥9 points in 252 patients
• Professor Zeng received a recognized clinical award from a major rehabilitation center
• Second-stage research on cognitive impairment and sleep disorders is being initiated with hospital partner

Negative

• Study was uncontrolled and single-center, with no randomization or control group
• Outcomes are explicitly not evidence of safety or efficacy and may reflect spontaneous recovery
• Data have not been peer reviewed and lack review or approval by any regulatory authority
• New research is investigational, not under FDA or comparable agency IND/IDE, with no assurance of completion or commercial product

Argus Aug 25 session 10 alerts

+2.52% close to close 16.9x rel. volume Open Argus

Details

News Market Reaction – UZX

+13.1% Peak in 1 hr 54 min

$8.61M Market Cap

On Aug 25, the day this news came out, UZX closed 2.52% above the previous close. Argus tracked a peak move of +13.1% during that session. Our momentum scanner recorded 10 alerts for this stock that day. Relative volume reached 16.9x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 25 session.

Key Figures

Study Duration: two years Study Population: 407 patients Patients Awakened: 32 patients +4 more

Study Duration

two years

Observational study of deep coma patients

Study Population

407 patients

Deep coma patients observed through December 2025

Patients Awakened

32 patients

During the observation period

Awakening Rate

7.86%

Of 407 deep coma patients in the observational study

GCS Improvement

252 patients

Recorded an increase of 9 points or more on the Glasgow Coma Scale

GCS Improvement Rate

61.9%

Patients recording an increase of 9 points or more

Research Stage

Phase II

Second-stage clinical research relating to cognitive impairment and sleep disorders

Historical Context

5 past events · Latest: Aug 11

5 events

1. Aug 11

   Hospitality technology expansion

   24h Move

   -32.8%

   Evaluated acoustic wellness applications for hotels without announcing signed commercial partnerships

2. Jul 27

   AI platform transformation

   24h Move

   +0.5%

   Unveiled Human Resonance OS as the foundation of an AI-enabled wellness ecosystem

3. Jun 30

   Half-year earnings

   24h Move

   -2.8%

   Reported lower revenue despite a narrower net loss for the six-month period

4. Jun 23

   Wellness ecosystem upgrade

   24h Move

   -4.9%

   Outlined AI wellness strategy and projected partnership and headphone revenue trends

5. Jun 05

   Nasdaq compliance notice

   24h Move

   -5.8%

   Received deficiency notice for falling below Nasdaq's minimum bid price requirement

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

observational study, control group, randomization, glasgow coma scale, +1 more

5 terms

observational study medical

"The study was an uncontrolled, single-center observational study"

An observational study is a type of research where investigators watch and record what happens to people who are already using a treatment or experiencing a condition, without assigning who gets what. Think of it like monitoring shoppers in a store rather than giving some a special product and others not. For investors, these studies provide real‑world evidence about safety, effectiveness and market use that can influence regulatory decisions, sales forecasts and perceived risk.

control group medical

"it did not include a control group or randomization"

A control group is a set of study subjects that does not receive the treatment or change being tested, providing a baseline to show what happens without the intervention. For investors, control groups matter because they help determine whether reported benefits are real or just coincidence or outside influences—think of testing a new recipe by comparing it against the original to see if the change truly improves the result.

randomization medical

"it did not include a control group or randomization"

Randomization is the process of assigning participants in a clinical study to different treatment groups by chance—like flipping a coin or drawing names from a hat—rather than by choice. That impartial assignment reduces bias and makes it more likely that differences in outcomes come from the treatments themselves, so investors can trust trial results as stronger evidence of a drug’s or device’s effectiveness and safety.

glasgow coma scale medical

"an increase of 9 points or more on the Glasgow Coma Scale"

A clinical tool that scores a person’s level of consciousness after a brain injury by testing eye, verbal, and motor responses; scores range from 3 (deep unconsciousness) to 15 (fully awake). It matters to investors because the score is a standardized medical outcome cited in trial results, safety reports, and regulatory filings, so changes in average scores or reported severe declines can affect perceptions of a treatment’s effectiveness or risk profile.

investigational new drug regulatory

"not being conducted under an investigational new drug or device application"

An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Award recognizes findings from a two-year observational study of 407 deep coma patients, in which 32 patients (7.86%) awakened, as Linkage Global and its hospital partner begin second-stage clinical research relating to cognitive impairment and sleep disorders

Tokyo, JAPAN and New York, NY, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Linkage Global Inc. (NASDAQ: UZX) (“Linkage Global” or the “Company”), a technology-driven enterprise focused on AI-enabled wellness infrastructure, today announced that Professor Zeng Yan, Chief Scientist at ClickClack, an intellectual property partner of Linkage Global, was awarded the “Clinical Contribution Award for Deep Coma Awakening” at the 3^rd Coma Awakening Specialty Rehabilitation Alliance Conference. The award, which was conferred by the Coma Arousal and Rehabilitation Center for Brain Disorders at the Guangdong Second Hospital of Traditional Chinese Medicine (the “Hospital”), recognizes Professor Zeng’s clinical research with the Hospital. The award coincides with Linkage Global and the Hospital initiating a second stage of clinical research relating to cognitive impairment and sleep disorders.

As the developer of the "Micro-brain" sonic healing system, Professor Zeng joined the team from the Hospital to release clinical research data from a two-year study and to outline potential areas of future collaboration. The study was an uncontrolled, single-center observational study of a non-invasive protocol combining micro-brain sound wave music with traditional acupuncture in deep coma patients, and it did not include a control group or randomization. As of December 2025, the research team had completed clinical observations and interventions involving 407 deep coma patients. Of those patients, 32 awakened during the observation period, representing 7.86% of the study population, and 252 patients (61.9%) recorded an increase of 9 points or more on the Glasgow Coma Scale (GCS). Because the study was uncontrolled, these observed outcomes cannot be attributed to the protocol, may reflect spontaneous recovery or concurrent care, and should not be understood as evidence of safety or efficacy. The data have not been peer reviewed, and no regulatory authority has reviewed or approved the protocol or any related product.

In recognition of the clinical exploration and outstanding contributions made by Professor Zeng and his team in the field of micro-brain acoustic wave-induced arousal, the Coma Arousal and Rehabilitation Center for Brain Disorders at the Guangdong Second Hospital of Traditional Chinese Medicine awarded Professor Zeng a trophy and certificate for the "Clinical Contribution Award for Deep Coma Awakening."

Building on the observational data described above, Linkage Global and the Guangdong Second Hospital of Traditional Chinese Medicine are initiating a second stage (“Phase II”) of clinical research relating to non-pharmacological approaches to cognitive impairment and sleep disorders. This research is investigational, is not being conducted under an investigational new drug or device application with the U.S. Food and Drug Administration or any comparable authority, and references to “Phase II” describe the parties’ own research sequence rather than a regulated clinical trial phase. There can be no assurance that this research will be completed, will produce favorable results, or will result in any commercially viable product.

“This recognition reflects the research work of Professor Zeng Yan and his team,” said Zhihua Wu, Chairman of Linkage Global. “Our current product portfolio centers on four primary lifestyle scenarios: carrying, sleeping, staying, and traveling. As we support the next stage of clinical research, we intend to continue informing our product architecture with research data while pursuing broader non-pharmacological wellness applications. Our longer-term objective is to compete in the mood-regulating equipment market across clinical and consumer applications, although we can give no assurance as to the outcome of the research or our ability to achieve that objective.”

About Linkage Global Inc.

Linkage Global Inc. (NASDAQ: UZX) is a technology-driven enterprise developing global AI-enabled wellness products and infrastructure. Through its proprietary Human Resonance OS, the Company integrates self-developed neural acoustic algorithms, a portfolio of original wellness audio copyrights, and smart wearables to deliver data-informed wellness solutions to B2B and B2C markets. The Company’s products are consumer wellness products and are not medical devices. Founded on March 24, 2022, Linkage Global is headquartered in Tokyo, Japan. For more information, visit: https://linkagecc.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, statements regarding the Company's plans, strategies, business development initiatives, the design, conduct, timing and anticipated results of clinical research, and the potential commercialization of acoustic wellness technologies. There can be no assurance that any strategic initiative, partnership, offering launch, clinical research project, or other business plan described herein will be successfully executed or completed. The clinical data described in this announcement are derived from an uncontrolled, single-center observational study conducted by a third-party hospital and research team, have not been peer reviewed or verified by any regulatory authority, and are not evidence that any Company product is safe or effective for any medical use. The Company’s products are consumer wellness products and are not intended to diagnose, treat, cure, or prevent any disease. This press release does not constitute guidance and should not be relied upon as indicative of future financial performance. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

Linkage Global Inc.
Investor Relations
Email: ir@linkagecc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What coma awakening results did Linkage Global (NASDAQ: UZX) report in August 2026?

According to Linkage Global, a two-year observational study in 407 deep coma patients saw 32 awaken and 252 record Glasgow Coma Scale increases of at least 9 points. The company emphasizes the uncontrolled design means results cannot be attributed to the protocol or treated as efficacy evidence.

What award did ClickClack’s Chief Scientist receive related to coma research at Linkage Global (UZX)?

According to Linkage Global, Professor Zeng Yan received the “Clinical Contribution Award for Deep Coma Awakening” from the Coma Arousal and Rehabilitation Center at Guangdong Second Hospital of Traditional Chinese Medicine, recognizing exploratory work on micro-brain acoustic wave-induced arousal based on a two-year observational study of 407 deep coma patients.

What is the new second-stage clinical research Linkage Global (UZX) is starting in 2026?

According to Linkage Global, the company and Guangdong Second Hospital are initiating a second-stage (“Phase II”) investigational program on non-pharmacological approaches to cognitive impairment and sleep disorders, based on prior observational data. This internal “Phase II” label does not represent a regulated clinical trial phase or FDA-reviewed study.

Are Linkage Global’s coma and sleep research protocols FDA approved or under an IND?

Linkage Global states the research is investigational and is not being conducted under an investigational new drug or device application with the U.S. FDA or comparable authorities. No regulatory body has reviewed or approved the protocol or any related product at this stage, according to the company.

Do the coma study results prove Linkage Global’s micro-brain system is safe or effective?

According to Linkage Global, the uncontrolled, single-center observational design means outcomes cannot be attributed to the protocol and may reflect spontaneous recovery or concurrent care. The company explicitly cautions the data should not be viewed as evidence of safety or efficacy or as clinical validation.

How does this coma research relate to Linkage Global (UZX) wellness products and strategy?

According to Linkage Global, its AI-enabled wellness portfolio targets carrying, sleeping, staying, and traveling scenarios, using neural acoustic algorithms and smart wearables. The company intends to use research insights to inform product architecture and pursue mood-regulating equipment markets, while giving no assurance on research success or commercialization.